209 related articles for article (PubMed ID: 32463176)
21. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
22. Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.
Lim KH; Chen CG; Chang YC; Chiang YH; Kao CW; Wang WT; Chang CY; Huang L; Lin CS; Cheng CC; Cheng HI; Su NW; Lin J; Chang YF; Chang MC; Hsieh RK; Lin HC; Kuo YY
Oncotarget; 2017 May; 8(20):32476-32491. PubMed ID: 28415571
[TBL] [Abstract][Full Text] [Related]
23. Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms.
Cavalloni C; Rumi E; Ferretti VV; Pietra D; Roncoroni E; Bellini M; Ciboddo M; Casetti IC; Landini B; Fugazza E; Troletti D; Astori C; Cazzola M
Oncotarget; 2017 May; 8(20):33416-33421. PubMed ID: 28422716
[TBL] [Abstract][Full Text] [Related]
24. Calreticulin mutation analysis in non-mutated Janus kinase 2 essential thrombocythemia patients in Chiang Mai University: analysis of three methods and clinical correlations.
Rattarittamrong E; Tantiworawit A; Kumpunya N; Wongtagan O; Tongphung R; Phusua A; Chai-Adisaksopha C; Hantrakool S; Rattanathammethee T; Norasetthada L; Charoenkwan P; Lekawanvijit S
Hematology; 2018 Oct; 23(9):613-619. PubMed ID: 29521158
[TBL] [Abstract][Full Text] [Related]
25. JAK2/STAT5 Pathway Mutation Frequencies in South African BCR/ABL Negative MPN Patients.
Shires KL; Rust AJ; Harryparsad R; Coburn JA; Gopie RE
Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):291-302. PubMed ID: 37023224
[TBL] [Abstract][Full Text] [Related]
26. Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis.
Jeong JH; Lee HT; Seo JY; Seo YH; Kim KH; Kim MJ; Lee JH; Park J; Hong JS; Park PW; Ahn JY
Ann Lab Med; 2016 Jul; 36(4):291-9. PubMed ID: 27139600
[TBL] [Abstract][Full Text] [Related]
27. Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR.
Zinke M; Nageswaran V; Reinhardt R; Burmeister T
Mol Diagn Ther; 2015 Oct; 19(5):329-34. PubMed ID: 26294037
[TBL] [Abstract][Full Text] [Related]
28. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.
Nunes DP; Lima LT; Chauffaille Mde L; Mitne-Neto M; Santos MT; Cliquet MG; Guerra-Shinohara EM
Blood Cells Mol Dis; 2015 Oct; 55(3):236-40. PubMed ID: 26227853
[TBL] [Abstract][Full Text] [Related]
29. The Calreticulin gene and myeloproliferative neoplasms.
Clinton A; McMullin MF
J Clin Pathol; 2016 Oct; 69(10):841-5. PubMed ID: 27354406
[TBL] [Abstract][Full Text] [Related]
30. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
[TBL] [Abstract][Full Text] [Related]
31. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
32. JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential Thrombocythaemia.
Pich A; Riera L; Francia di Celle P; Beggiato E; Benevolo G; Godio L
Acta Haematol; 2018; 140(4):234-239. PubMed ID: 30404086
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
[TBL] [Abstract][Full Text] [Related]
34. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.
Czech J; Cordua S; Weinbergerova B; Baumeister J; Crepcia A; Han L; Maié T; Costa IG; Denecke B; Maurer A; Schubert C; Feldberg K; Gezer D; Brümmendorf TH; Müller-Newen G; Mayer J; Racil Z; Kubesova B; Knudsen T; Sørensen AL; Holmström M; Kjær L; Skov V; Larsen TS; Hasselbalch HC; Chatain N; Koschmieder S
Leukemia; 2019 Apr; 33(4):995-1010. PubMed ID: 30470838
[TBL] [Abstract][Full Text] [Related]
35. [Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases].
Li ZL; Gao L; Zhang H; Zhang CX; Chen YR; Huang FZ; Gong M; Gao YY; Tang Y; Ma YG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1122-1128. PubMed ID: 30111418
[TBL] [Abstract][Full Text] [Related]
36. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
[TBL] [Abstract][Full Text] [Related]
37. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
[TBL] [Abstract][Full Text] [Related]
38. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
[TBL] [Abstract][Full Text] [Related]
39. [Relationship between Calreticulin Gene Mutation and JAK2/MPL Negative Myeloproliferative Neoplasms].
Dong L; Shen XL; Wei W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1532-4. PubMed ID: 26524072
[TBL] [Abstract][Full Text] [Related]
40. Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.
Tvorogov D; Thompson-Peach CAL; Foßelteder J; Dottore M; Stomski F; Onnesha SA; Lim K; Moretti PAB; Pitson SM; Ross DM; Reinisch A; Thomas D; Lopez AF
EMBO Rep; 2022 Apr; 23(4):e52904. PubMed ID: 35156745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]